Trial Profile
A multicentre, open-label, randomised, controlled trial for the effect and safety of Afatinib with Nivolumab in the treatment of gallbladder carcinoma with ERBB2/3 mutation
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2018
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Nivolumab (Primary)
- Indications Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 07 Sep 2018 New trial record